Revance expects to reach positive adjusted EBITDA in 2025

The company states: “In September 2023, Revance revised its 2023 GAAP and Non-GAAP operating expense guidance to reflect the company’s exit of the OPUL payments business. Revance expects its 2023 GAAP operating expenses to be $545 million to $585 million and non-GAAP operating expenses, which exclude costs of revenue, depreciation and amortization, stock-based compensation, and restructuring and impairment charges to be $315 million to $335 million. Revance expects its 2023 non-GAAP research and development expense to be $75 million to $85 million. The company’s non-GAAP operating expense guidance for 2023 primarily reflects increased investments in its aesthetics commercial infrastructure, including sales team expansion, and DAXXIFY and RHA Collection commercial investments. With current cash, cash equivalents, short-term investments and anticipated revenues and expenditures, management projects that the company will be funded to cash flow break-even and expects to reach positive Adjusted EBITDA in 2025.”